ERNA ETERNA THERAPEUTICS INC.

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Access the “What This Means” segment 

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a .

As part of the segment, Sanjeev Luther, President and CEO of Ernexa, discussed the Company’s with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa's lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.

The Virtual Investor “What This Means” segment featuring Ernexa can be accessed .

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit .

Media Contact

Sharon Golubchik

RAYNZ

Investor Contact

Jenene Thomas

JTC Team, LLC

(908) 824-0775



EN
06/11/2025

Underlying

ERNAETERNA THERAPEUTICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ETERNA THERAPEUTICS INC.

 PRESS RELEASE
Free
ERNA ETERNA THERAPEU...

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting...

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials The Company’s operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1 study in platinum-resistant ovarian cancer (PROC), anticipated in H2 2026 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), developing innovative cell therapies for the treatment of a...

6h / 55m 1 EN
 PRESS RELEASE
Free
ERNA ETERNA THERAPEU...

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bio...

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform Access the “What This Means” segment  CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a . As part of the segment, Sanjeev Luther, President and CEO of Ernexa, discussed the Company’s with Cellipont Bioservices focused on Engineering, Differe...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ERNA ETERNA THERAPEU...

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell...

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its upcoming company presentation at the , taking place on October 7 in Phoenix, Arizona, and virtually online. “We are honored to participate in the Cell & Gene Meeting on the Mesa, one of the most important gatherings for advancing cell and gene therapies,” said Sanjeev Luther, President and CEO of Ernexa Ther...

October 1, 2025 1 EN
 PRESS RELEASE
Free
ERNA ETERNA THERAPEU...

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Exper...

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjeev Luther, will participate in a featured panel discussion at the upcoming 5th Annual on October 1 in Boston. “Participation in the iPSC Drug Development Summit provides Ernexa the opportunity to contribute to important conversations shaping the future ...

September 29, 2025 1 EN
 PRESS RELEASE
Free
ERNA ETERNA THERAPEU...

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR S...

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trials CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced preclinical data will be presented at the inaugural . The oral presentation, taking place on September 2...

September 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch